667 related articles for article (PubMed ID: 21720655)
41. Low systemic absorption and good tolerability of pimecrolimus, administered as 1% cream (Elidel) in infants with atopic dermatitis--a multicenter, 3-week, open-label study.
Staab D; Pariser D; Gottlieb AB; Kaufmann R; Eichenfield LF; Langley RG; Scott G; Ebelin ME; Barilla D; Schmidli H; Burtin P
Pediatr Dermatol; 2005; 22(5):465-71. PubMed ID: 16191004
[TBL] [Abstract][Full Text] [Related]
42. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study.
Meurer M; Fölster-Holst R; Wozel G; Weidinger G; Jünger M; Bräutigam M;
Dermatology; 2002; 205(3):271-7. PubMed ID: 12399676
[TBL] [Abstract][Full Text] [Related]
43. Control of atopic eczema with pimecrolimus cream 1% under daily practice conditions: results of a > 2000 patient study.
Ring J; Abraham A; de Cuyper C; Kim K; Langeland T; Parra V; Pigatto P; Reunala T; Szczepanski R; Möhrenschlager M; Bräutigam M; Rossi AB; Meents-Kopecky E; Schneider D
J Eur Acad Dermatol Venereol; 2008 Feb; 22(2):195-203. PubMed ID: 18211413
[TBL] [Abstract][Full Text] [Related]
44. Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta-analysis of randomized clinical trials.
Chen SL; Yan J; Wang FS
J Dermatolog Treat; 2010 May; 21(3):144-56. PubMed ID: 20394490
[TBL] [Abstract][Full Text] [Related]
45. Topical pimecrolimus: a review of its clinical potential in the management of atopic dermatitis.
Wellington K; Jarvis B
Drugs; 2002; 62(5):817-40. PubMed ID: 11929333
[TBL] [Abstract][Full Text] [Related]
46. Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: a randomized, investigator-blind comparison.
Draelos Z; Nayak A; Pariser D; Shupack JL; Chon K; Abrams B; Paul CF
J Am Acad Dermatol; 2005 Oct; 53(4):602-9. PubMed ID: 16198779
[TBL] [Abstract][Full Text] [Related]
47. Safety and tolerability of 1% pimecrolimus cream among infants: experience with 1133 patients treated for up to 2 years.
Paul C; Cork M; Rossi AB; Papp KA; Barbier N; de Prost Y
Pediatrics; 2006 Jan; 117(1):e118-28. PubMed ID: 16361223
[TBL] [Abstract][Full Text] [Related]
48. Treatment with pimecrolimus cream 1% clears irritant dermatitis of the periocular region, face and neck.
Mensing CO; Mensing CH; Mensing H
Int J Dermatol; 2008 Sep; 47(9):960-4. PubMed ID: 18937664
[TBL] [Abstract][Full Text] [Related]
49. Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis.
Luger TA; Lahfa M; Fölster-Holst R; Gulliver WP; Allen R; Molloy S; Barbier N; Paul C; Bos JD
J Dermatolog Treat; 2004 Jun; 15(3):169-78. PubMed ID: 15204150
[TBL] [Abstract][Full Text] [Related]
50. Clinical and cytological effects of pimecrolimus cream 1% after resolution of active atopic dermatitis lesions by topical corticosteroids: a randomized controlled trial.
Bangert C; Strober BE; Cork M; Ortonne JP; Luger T; Bieber T; Ferguson A; Ecker RC; Kopp T; Weise-Riccardi S; Guettner A; Stingl G
Dermatology; 2011 Feb; 222(1):36-48. PubMed ID: 21150167
[TBL] [Abstract][Full Text] [Related]
51. The role of topical calcineurin inhibitors in atopic dermatitis.
Alomar A; Berth-Jones J; Bos JD; Giannetti A; Reitamo S; Ruzicka T; Stalder JF; Thestrup-Pedersen K;
Br J Dermatol; 2004 Dec; 151 Suppl 70 Dec 2004():3-27. PubMed ID: 15548171
[TBL] [Abstract][Full Text] [Related]
52. Topical pimecrolimus in the treatment of human allergic contact dermatitis.
Amrol D; Keitel D; Hagaman D; Murray J
Ann Allergy Asthma Immunol; 2003 Dec; 91(6):563-6. PubMed ID: 14700441
[TBL] [Abstract][Full Text] [Related]
53. Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies.
Paller AS; Lebwohl M; Fleischer AB; Antaya R; Langley RG; Kirsner RS; Blum RR; Rico MJ; Jaracz E; Crowe A; Linowski GJ;
J Am Acad Dermatol; 2005 May; 52(5):810-22. PubMed ID: 15858471
[TBL] [Abstract][Full Text] [Related]
54. Addition of pimecrolimus cream 1% to a topical corticosteroid treatment regimen in paediatric patients with severe atopic dermatitis: a randomized, double-blind trial.
Meurer M; Eichenfield LF; Ho V; Potter PC; Werfel T; Hultsch T
J Dermatolog Treat; 2010 May; 21(3):157-66. PubMed ID: 20394491
[TBL] [Abstract][Full Text] [Related]
55. Pimecrolimus 1% cream for oral erosive lichen planus: a 6-week randomized, double-blind, vehicle-controlled study with a 6-week open-label extension to assess efficacy and safety.
McCaughey C; Machan M; Bennett R; Zone JJ; Hull CM
J Eur Acad Dermatol Venereol; 2011 Sep; 25(9):1061-7. PubMed ID: 21175873
[TBL] [Abstract][Full Text] [Related]
56. Belgian observational drug utilization study of pimecrolimus cream 1% in routine daily practice in atopic dermatitis.
De Backer M; Morren MA; Boonen H; Boyden B; Vertruyen A; Lecomte P; Paquay C; Lesaffre E; Lambert J
Dermatology; 2008; 217(2):156-63. PubMed ID: 18525202
[TBL] [Abstract][Full Text] [Related]
57. Efficacy and safety of pimecrolimus cream 1% in adult patients with vitiligo: results of a randomized, double-blind, vehicle-controlled study.
Dawid M; Veensalu M; Grassberger M; Wolff K
J Dtsch Dermatol Ges; 2006 Nov; 4(11):942-6. PubMed ID: 17081269
[TBL] [Abstract][Full Text] [Related]
58. Pimecrolimus: new preparation. Me-too: too many risks, not beneficial enough in atopic dermatitis.
Prescrire Int; 2004 Dec; 13(74):209-12. PubMed ID: 15599989
[TBL] [Abstract][Full Text] [Related]
59. Topical tacrolimus and pimecrolimus: future directions.
Ling MR
Semin Cutan Med Surg; 2001 Dec; 20(4):268-74. PubMed ID: 11770914
[TBL] [Abstract][Full Text] [Related]
60. Randomized trial of pimecrolimus cream versus triamcinolone acetonide paste in the treatment of oral lichen planus.
Gorouhi F; Solhpour A; Beitollahi JM; Afshar S; Davari P; Hashemi P; Nassiri Kashani M; Firooz A
J Am Acad Dermatol; 2007 Nov; 57(5):806-13. PubMed ID: 17658663
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
